PDCD1 and malignant colon neoplasm: Combined blockade of PD-1/PD-L1 and TIGIT exhibited a more powerful anti-tumor effect in colon cancer, melanoma, and glioblastoma (GBM) compared with that of monotherapy (6, 65, 118, 119).